The results come as Pfizer and other drugmakers grapple with Trump's calls to lower U.S. drug prices and brace for his planned tariffs on pharmaceuticals.
Pfizer
on Tuesday hiked its full-year adjusted profit guidance on its cost cuts and strong business performance this year.
The company also reported second-quarter results that topped Wall Street’s estimates for the period.
Pfizer now expects full-year adjusted profit to come in between $2.90 to $3.10, up from a previous guidance of $2.80 to $3 per share.
The company maintained its 2025 revenue forecast of $61 billion to $64 billion.
Pfizer hiked its full-year profit guidance, citing its strong business performance and cost cuts, even as sales for the period…
Pfizer is looking to newer products and acquisitions to offset a declining Covid business.
The pharmaceutical giant reaffirmed the modest 2026 outlook that rattled investors in December.
Pfizer has pursued deals of all sizes to build new revenue streams, but the outlook underscores that those investments are still…
Ricavi pari a 14,45 miliardi di dollari, a fronte di stime pari a 13,79 miliardi, mentre l’utile rettificato è di 75 centesimi…
Merck said its narrowed profit guidance reflects several new items, including "lower estimated costs related to the impact of…
